Abstracts tagged "Malignancy"

Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 1694 • 2015 ACR/ARHP Annual Meeting
All-Cause Mortality and Malignancies in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Philip J. Mease¹, Alice B. Gottlieb², Alan Menter³, Christopher T. Ritchlin⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor Research Institute, Dallas, TX, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Describe characteristics and incidence rates of all-cause mortality and malignancies (excluding NMSC) in psoriasis pts with psoriatic arthritis (PsA) from PSOLAR. Methods: PSOLAR is…
Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Takuma Tsuzuki Wada¹, Yuji Akiyama¹ and Toshihide Mimura², ¹Department of Rheumatology & Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…
Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Yoshiya Tanaka¹, Tsutomu Takeuchi², Hisashi Yamanaka³, Naonobu Sugiyama M.D., Ph.D⁴, Takunari Yoshinaga⁴, Kanae Togo⁴, Jamie Geier⁵, Mary Boy⁵ and Carol Connell⁵, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Pfizer Japan Inc, Tokyo, Japan, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…
Abstract Number: 2141 • 2015 ACR/ARHP Annual Meeting
Risk of Cancer in Non-TNFi Biologics-Treated RA
Hjalmar Wadström¹, Johan Askling² and the ARTIS study group, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Clinical Epidemiology Unit and Rheumatology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Immune incompetence may lower host surveillance against incipient tumours. Conversely, immune therapies have emerged as a promising therapeutic approach to cancer. Malignancies thus constitute…
Abstract Number: 2664 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Hematological Malignancies in Children Born to Women with SLE
Evelyne Vinet¹, Ann E. Clarke², Christian A. Pineau³, Susan Scott⁴, Robert W. Platt⁵ and Sasha Bernatsky⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose Patients with SLE have an increased risk of hematological malignancies, particularly non-Hodgkin lymphoma, compared to the general population. Recently, in utero exposures, such as…
Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting
Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience
David Fiorentino¹, Mark Lebwohl², Vincent Ho³, Richard Langley⁴, Kavitha Goyal⁵, Steve Fakharzadeh⁶, Steve Calabro⁵ and Wayne Langholff⁷, ¹Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ²Mount Sinai Medical Center, New York, NY, ³University of British Columbia, Vancouver, BC, Canada, ⁴Dalhousie University, Halifax, NS, Canada, ⁵Janssen Services, LLC, Horsham, PA, ⁶Janssen Services, LLC, Spring House, PA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
Abstract Number: 1265 • 2014 ACR/ARHP Annual Meeting
Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase
Pari Basharat¹, Arash Lahouti H.¹, Andrew L. Mammen², Iago Pinal-Fernandez¹, Tanmayee Bichile³, Thomas E. Lloyd⁴, Sonye K. Danoff⁵, Livia Casciola-Rosen⁶ and Lisa Christopher-Stine⁷, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Neurology and Medicine, Johns Hopkins University, Baltimore, MD, ³Rehumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Neurology, Johns Hopkins, Baltimore, MD, ⁵Medicine/Pulmonary, Johns Hopkins University, Baltimore, MD, ⁶Center Tower Ste 5300, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose The idiopathic inflammatory myopathies (IIM) comprise a group of autoimmune disorders that target skeletal muscle. Some IIM cases may be associated with an autoantibody…
Abstract Number: 460 • 2014 ACR/ARHP Annual Meeting
Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program
Jeffrey R. Curtis¹, E.B. Lee², G. Martin³, X. Mariette⁴, K.K. Terry⁵, Y. Chen⁶, J. Geier⁷, J. Andrews⁵, M. Kaur⁶, K. Kwok⁷ and C. Nduaka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Seoul National University College of Medicine, Seoul, South Korea, ³Dermatology and Laser Center of Maui, Kihei, HI, ⁴Paris-Sud University, Paris, France, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The incidence of non-melanoma skin cancer (NMSC) in the tofacitinib…
Abstract Number: 2901 • 2013 ACR/ARHP Annual Meeting
Standardized Incidence Ratios For Cancer After Renal Transplant In Systemic Lupus Erythematosus and Non-Systemic Lupus Erythematosus Recipients
Rosalind Ramsey-Goldman¹, Amarpali Brar², Moro Salifu², Ann E. Clarke³, Rahul M. Jindal⁴ and Sasha Bernatsky³, ¹Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine, SUNY Downstate, Brooklyn, NY, ³McGill University, Montreal, QC, Canada, ⁴Surgery, Uniformed Services University and George Washington University, Washington, DC
Background/Purpose: Differentiating between effects of drugs vs. disease activity on cancer risk in SLE is difficult. Because all renal transplant recipients are on similar immunomodulatory…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 1037 • 2013 ACR/ARHP Annual Meeting
Incidence Of Malignancy In Patients With Rheumatoid Arthritis From a Japanese Large Observational Cohort (NinJa)
Atsushi Hashimoto¹, Noriyuki Chiba², Jinju Nishino³, Toshihiro Matsui⁴ and Shigeto Tohma⁵, ¹Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ²Department of Rheumatology, Morioka National Hospital, NHO, Iwate, Japan, ³Nishino Clinic, Orthopedics and Rheumatology, Tokyo, Japan, ⁴Department of Rheumatology, Sagamihara Hospital, National Hospital Organization, Kanagawa, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose :Patients with rheumatoid arthritis (RA) die mainly of cardiovascular/cerebrovascular diseases, respiratory diseases, infections, or malignancies. In recent years, the ratio of infections and respiratory…
Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
X. Mariette¹, J. R. Curtis², E. B. Lee³, B. Benda⁴, I. Kaplan⁵, K. Soma⁵, R. Chew⁵, J. Geier⁶, L. Wang⁷ and R. Riese⁵, ¹Paris-Sud University, Paris, France, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
Abstract Number: 782 • 2013 ACR/ARHP Annual Meeting
Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Johan Askling¹, Niklas Berglind², Stefan Franzén², Thomas Frisell³, Christopher Garwood⁴, Jeffrey D. Greenberg⁵, Meilien Ho⁶, Marie Holmqvist¹, Laura Horne⁷, Kathy Lampl⁸, Kaleb Michaud⁹, Fredrik Nyberg¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁴, Hisashi Yamanaka¹⁵ and Deborah Symmons⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²AstraZeneca R&D Mölndal, Mölndal, Sweden, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁷AstraZeneca, Wilmington, DE, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰AstraZeneca R&D, Mölndal, Sweden, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer…
Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting
Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials
Carolina Mejia-Otero¹, Carlos J. Lozada² and Luis Arias-Urdaneta³, ¹Internal Medicine, Mount Sinai Medical Center, Miami, FL, ²Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, Mount Sinai Medical Center, Miami Beach, FL
Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…